Trevi Therapeutics Stock Surges as Analysts Predict Major Upside
Published on 11/07/2025 at 10:09 | Redaktion boerse-global.de
Trevi Therapeutics shares are demonstrating remarkable momentum with a sustained upward trajectory that has captured market attention. In the latest trading session, the biopharmaceutical company’s stock advanced by 3.48%, closing at $11.01. This represents the sixth positive session within a ten-day trading period, highlighting consistent investor confidence. Trading activity occurred between $10.56 and $11.11 with elevated volume indicators suggesting significant institutional participation.
Market researchers have expressed strong conviction in Trevi’s prospects, with nine analytical firms collectively establishing a price target of $20.72. This projection indicates substantial growth potential of approximately 95% from current levels. The consensus rating stands at “Strong Buy,” reinforced by an average score of 1.25, reflecting expert confidence in the biotechnology firm’s long-term value Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
